Fly News Breaks for February 27, 2020
Feb 27, 2020 | 12:21 EDT
Piper Sandler analyst Edward Tenthoff lowered the firm's price target on Exelixis to $23 from $35 and reiterates an Overweight rating on the shares. Slowing sales growth and faster operating expenditure growth brought the analyst's non-GAAP earnings per share estimate to decline from $1.16 in 2019 to 44c in 2020 and 33c in 2021. However, he anticipates positive data could lead to cabozantinib label expansions and reaccelerate product sales growth in 2021.
News For EXEL From the Last 2 Days